Biohaven Ltd.
BHVN
Positions held
Your positionsBHVN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Biohaven Ltd. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, particularly in areas like neurology and pain management.
- The company's market capitalization is approximately $1.82 billion, indicating a significant valuation in the biotech space.
- Analysts have a 'buy' recommendation for Biohaven, with a target mean price of $21.27, suggesting potential upside from current levels.
- Biohaven has faced substantial financial challenges, with a net income of -$738.82 million in 2025, reflecting ongoing operational losses.
- The company has reported zero revenue for multiple quarters, including the last four quarters, highlighting a critical lack of product sales.
- Current market signals indicate a 'Strong Sell' with a score of -26.00, driven by negative trends and technical indicators.
Fundamentals
| Market cap | $1.80B | Enterprise value | $1.83B | Trailing P/E | — | Forward P/E | -6.37 |
| PEG | — | Price / book | 147.28 | Beta | 3.20 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -8.0% | ROA | -72.0% | Debt / equity | 24.30 |
| Current ratio | 4.73 | Free cash flow | -$256.22M | Analyst recommendation | buy | Mean target | $21.27 |
| 52w high | $18.57 | 52w low | $7.48 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$137M | -$131M | -$146M | -$173M | -$198M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$125M | -$130M | -$143M | -$169M | -$212M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$739M | -$846M | -$408M | -$570M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$745M | -$885M | -$436M | -$568M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Sector Update: Healthcare Stocks Decline Pre-Bell Thursday
2026-10-08 · Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
2026-10-08 · Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
2026-10-02 · Roche’s AI lab; Biohaven’s pivotal pause
2026-09-29 · Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
2026-09-25 · Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?
2026-09-18 · Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
2026-09-18 · Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
2026-09-18 · Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says
2026-09-11 · Biohaven’s epilepsy drug hit with FDA clinical hold
Price (daily)
Full chart · RSI · MACD · patterns